Nuclea snags Wilex AG subsidiary; Gentris expands genomic biomarker offering;

> Massachusetts diagnostics outfit Nuclea Biotechnologies is snatching up the U.S. subsidiary of Germany's Wilex AG, a biopharma focused on developing diagnostic and drug candidates for cancer. Nuclea is known for identifying biomarkers and developing proprietary diagnostic tests under the brand "Decision Dx" that help predict the best possible treatments for specific patients depending on their genetic makeup. Story

> Gentris is expanding its genomic biomarker offering with the launch of Affymetrix GeneChip Human Transcriptome Array services. Release

Suggested Articles

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

Drug-pricing watchdog ICER has partnered with medical data firm Aetion to help analyze the real-world performance of different treatments.